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Blockade of IL-33 release and suppression of type
2 innate lymphoid cell responses by helminth
secreted products in airway allergy
HJ McSorley1, NF Blair1, KA Smith1, ANJ McKenzie2 and RM Maizels1
Helminth parasites such as the nematode Heligmosomoides polygyrus strongly inhibit T helper type 2 (Th2) allergy, as
well as colitis and autoimmunity. Here, we show that the soluble excretory/secretory products of H. polygyrus (HES)
potently suppress inflammation induced by allergens from the common fungus Alternaria alternata. Alternaria extract,
when administered to mice intranasally with ovalbumin (OVA) protein, induces a rapid (1–48h) innate response while
alsopriminganOVA-specific Th2 response that canbeevoked14days later by intranasal administrationofOVAalone. In
this model, HES coadministration with Alternaria/OVA suppressed early IL-33 release, innate lymphoid cell (ILC)
production of IL-4, IL-5, and IL-13, and localized eosinophilia. Upon OVA challenge, type 2 ILC (ILC2)/Th2 cytokine
production and eosinophilia were diminished in HES-treatedmice. HES administration 6h beforeAlternariablocked the
allergic response, and its suppressive activity was abolished by heat treatment. Administration of recombinant
IL-33 at sensitization with Alternaria/OVA/HES abrogated HES suppression of OVA-specific responses at challenge,
indicating that suppression of early Alternaria-induced IL-33 release could be central to the anti-allergic effects of HES.
Thus, this helminth parasite targets IL-33 production as part of its armory of suppressive effects, forestalling the
development of the type 2 immune response to infection and allergic sensitization.
INTRODUCTION
The prevalence of allergic asthma has increased dramatically in
developed countries over the last century,1 while over the same
period the incidence of infections, especially with parasites, has
sharply decreased. This has led to the hypothesis that the
immune system is modulated in the presence of parasitic
infections, and in their absence is prone to hyperactivity leading
to immune-mediated diseases such as autoimmunity, inflam-
matory bowel disease, and allergy.2–4
Asthma is amultifactorial condition, characterized by airway
obstruction, hyperactivity of the airways to stimuli, and fibrosis
of the lungs.5 Most asthmatic individuals are characterized by a
T helper type 2 (Th2) response to allergens, with increased type
2 cytokines and eosinophilia in the lungs. Recently, the critical
roles of both the airway epithelium,6 and newly described type 2
innate lymphoid cells (ILC2s)7–11 in the initiation and
maintenance of asthma have been established. Thus, asthmatic
inflammation develops through the concerted action of innate
and adaptive immunity, and it is not yet known at what level
helminth infection could act to suppress pathology.
Many asthmatic individuals are allergic to fungal molds, and
the presence of fungi such asAlternaria in the household during
early life predicts the development of asthma in later life.12High
atmospheric concentrations of fungal spores (for instance
during thunderstorms) also correlates with increased hospital
admissions due to asthma exacerbations.13 Thus, fungal molds
may be important both as initiators and as targets of allergic
responses.14
Alternaria extract is known to provoke allergic immune
responses in mice, both in chronic Th2-mediated15,16 and in
acute T cell-independent administration regimes.7,17–19 Thus it
is an ideal setting inwhich to examine the relative roles of innate
and adaptive type 2 responses during asthmatic pathology, and
the effect of helminths and their products on these responses.
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The development of lung eosinophilia to Alternaria extract in
the early (o3 days post administration) phase can be attributed
to Alternaria-induced ILC2 activation and IL-5 and IL-13
production.7 ILCs, a non-B, non-T lymphocyte subset that
expresses ICOS, CD44, CD25, and ST2 (the IL-33 receptor),
respond to the alarmin cytokines IL-25 or IL-33 by producing
large amounts of IL-5 and IL-13, are required for resistance to
some parasites,20 and are instrumental for allergic responses in
the lung.7–11 After Alternaria administration, both early ILC2
responses and eosinophilia have been shown to be critically
dependent on IL-33 signaling, and were abrogated or ablated in
IL-33-, ST2- (IL-33 receptor) or MyD88- (the IL-33-receptor
signaling adaptor) deficient mice.7,17,21 Critically, these early
responses are unchanged in recombinase-activating gene
(RAG)-deficient mice and are therefore independent of the
adaptive immune system.7,17
Heligmosomoides polygyrus is a natural parasite of wild mice,
which is used as a laboratory model of chronic intestinal
helminth infection.22 H. polygyrus infection has multiple
immunomodulatory effects including induction of regulatory
T cells,23,24 regulatory B cells,25 and suppressive or suppressed
dendritic cells.26–28 Infection also suppresses inflammatory
responses in models of asthma, food allergy, diabetes, and
colitis.4 Many of the suppressive effects of infection can be
attributed to H. polygyrus excretory/secretory (HES) products,
including Treg induction29 and dendritic cell suppression.26,30
Our aim is to identify suppressivemolecules in HESwith a view
to develop these as novel therapeutic agents for human disease.
Recently, we described suppression of allergic airway
responses in an alum adjuvant-dependent model of asthma
by coadministration of HES.31 Alum-mediated sensitization is
effected by the intraperitoneal route, and while this stimulates a
strong pro-allergic Th2 response, initiating events may not well
represent those at the airway epithelium. In particular, early
lung alarmin responses are not induced during intraperitoneal
alum administration, and ovalbumin (OVA)-Alum model
responses (unlike those induced by Alternaria) are intact in
MyD88-deficient mice, which lack receptor signaling from
IL-1-family cytokines such as IL-33.32 In studying interactions
between the innate and adaptive compartments, we therefore
decided to examine a protocol in which airway inflammation is
dependent on sensitization directly within the airways, using
the clinically relevant Alternaria allergen and the model T-cell
antigen OVA. As presented below, the HES products of
H. polygyrus proved to be highly efficacious at suppressing the
allergic response evoked in the airways.
RESULTS
HES suppresses inflammation and pathology in a mouse
model of asthma
In studying how helminth parasites may modulate allergic
responses, we previously reported thatH. polygyrus infection,33
or the administration of secreted products from cultured
parasites (HES31) is able to suppress the expression of airway
allergic inflammation in mice primed with allergens in alum
adjuvant by the intraperitoneal route. Because this mode of
sensitization is not physiologically related to the development
of human asthma, we tested the ability of HES to inhibit allergy
following airway sensitization, in a model of asthma similar to
that described by Kobayashi et al.15
Mice were sensitized by intranasal administration of OVA
protein with extract of the fungal organism Alternaria
alternata, and the OVA-specific response was measured
following the intranasal delivery of OVA protein alone 14
days later (Figure 1a). OVA challenge elicited a substantial
eosinophilic infiltrate in the bronchoalveolar lavage (BAL) and
lung tissue of mice which had been primed with OVA in the
presence of Alternaria (Figure 1b,c; Supplementary Figure 1
online), while little change in neutrophils was observed
(Figure 1d). No inflammation was seen in mice primed
with soluble OVA alone, and only slight infiltration in animals
receiving a phosphate-buffered saline (PBS) sham airway
challenge (Figure 1e).
When HES was coadministered with the sensitizing dose,
however, a striking reduction in inflammation was seen
(Figure 1b,c,e; Supplementary Figure 1), with eosinophils
reduced to levels of unchallenged mice. The suppressive effect
of HES was ablated by heating to 95 1C for 20min before
administration (Figure 1f), implying that this activity is
dependent on native protein conformation, and is in
contrast to the heat-stable suppressive effects of HES when
administered at sensitization in the OVA-Alum model of
asthma.31 Notably, HES is known to contain a heat-labile
molecule with the ability to signal through the mammalian
TGF-b receptor.29 To investigate the role of the TGF-b
pathway, we tested the effect of administering an amount
of recombinant TGF-b which equated to the activity within
HES. At the same time, we also tested Bovine Serum Albumin
(BSA) as an unrelated protein to examine whether any form of
antigen competition was reducing the allergic response to
OVA. In neither case could the suppressive effect of HES be
recapitulated (Figure 1g).
HES suppresses both innate and adaptive type 2 immunity
The allergic response in OVA-Alternaria-primed mice dis-
played all the canonical features of type 2 immune respon-
siveness. Thus, the type 2 cytokines IL-4 and IL-5 were
significantly upregulated in BAL supernatants from allergic
mice, along with a trend for increased IL-13 (Figure 2a).
In mice receiving HES at priming, these cytokine res-
ponses were suppressed without any evident switch to IFN-
g or IL-17A (Figure 2a). BAL fluids also contained elevated
levels of the type 2 myeloid cell response markers RELM-a and
Ym1,34 which were again suppressed byHES coadministration,
although only significantly so in the case of RELM-a
(Figure 2b).
Within the lungs of sensitized mice, the dominant Th2
response was reflected by enhanced ex vivo intracellular
staining of lymphocytes for IL-4, IL-5, and IL-13 by CD4þ
T cells, alongside a small increase in IFN-g and a trend for
increased IL-17A production. Th2 cytokine expression was
diminished in recipients of HES (Figure 2c), although to a
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lesser degree than noted for total cytokines in the BAL
(Figure 2a). We also examined the ILC compartment, defined
by expression of ICOS in the absence of classical lineage
markers (ICOSþLineage–). A marked increase in the
production of IL-4, as well as IL-5 and IL-13, was found
within this subset in allergic mice each of which was almost
completely abolished in mice that had received HES at
sensitization (Figure 2d; Supplementary Figure 2).
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Figure 1 Alternaria-induced allergic inflammation to ovalbumin (OVA) challenge is suppressed byH. polygyrusexcretory-secretory (HES) products. (a)
Schematic of the Alternariamodel: OVA protein (20 mg) was administered to BALB/c mice intranasally, with or without 50 mg Alternaria extract and 10mg
HES. Twoweeks later, mice were challenged by intranasal (IN) administration of 20 mgOVA or phosphate-buffered saline (PBS) for 3 days, and samples
taken at day 17. (b) Numbers of SiglecFþCD11c– eosinophils in bronchoalveolar lavage (BAL) fluid determined by flow cytometry. (c, d) Lung cell
suspensions were analyzed by flow cytometry for eosinophils (as in panel b) and neutrophils (GR1hiCD11bhiSiglecfCD11c ). (e) Formalin-fixed lungs
were sectioned and stained by Hemotoxylin and Eosin (H&E) or Periodic Acid Schiff (PAS). Representative sections are presented, scale bar¼ 100 mm.
(f) HES was heat treated at 95 1C for 20min (HT-HES) before administration, and numbers of BAL SiglecFþCD11c– eosinophils counted. (g) BAL
eosinophils frommice treatedwithAlternaria,OVA, andHESasdescribed in panela, orwith 4 ng rTGF-b (TGF), or 10mgBovineSerumAlbumin (BSA) as
indicated. Data in panels b–d are representative of five repeat experiments, 3–5 per mice group, in panel f are pooled from two repeat experiments, total
n¼7 per group, and in panel g are representative of two repeat experiments with four mice per group. ***Po0.001, **Po0.01, *Po0.05, and NS, not
significant.
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We further characterized cytokine-producing cells in the
lungs of these mice by calculating absolute numbers of CD4þ
T cell and ILC2 cytokine-producing cells (Figure 2e,f). Both
IL-4-, IL-5-, and IL-13-producing CD4þ T cells and ILC2s
were dramatically reduced by HES coadministration. Although
numbers of ILC2s producing IL-4, IL-5, and IL-13 in allergic
mice were respectively 50-fold, 3-fold, and 10-fold lower than
cytokine-producing CD4þ T cells, the reduction in cytokine-
producing cell numbers with HES addition in ILC2s was 6.6-,
4.9-, and 8.3-fold, and inCD4þ T cells it was only 3.2-, 3.4-, and
3.7-fold, respectively. With the known ability of ILC2s to make
extremely large amounts of IL-5 and IL-13,35 they are likely to
0
5
10
15
IFNγ IL-4 IL-5 IL-13 IL-17A
###
*
**
###
###
###
%
 O
f C
D4
+T
cR
B+
0
2
4
6
IFNγ IL-4 IL-5 IL-13 IL-17A
** *
###
##
pg
 m
l–1
0
5,000
10,000
15,000
20,000
RELMα Ym1
***
###
##
n
g 
m
l–1
a b
c
0
10
20
30
40
50
IL
-4
+%
 o
f
CD
4+
KJ
12
6+
*
Alt Alt Alt
OVA OVA OVA OVA
HES
OVA PBS OVA OVA
0
5
10
15
IL
-1
3+
%
 o
f
IC
O
S+
lin
ea
ge
- *** *
Alt Alt Alt
OVA OVA OVA OVA
HES
OVA PBS OVA OVA
0
10
20
30
40
50
Fo
xp
3+
%
 o
f
CD
4+
KJ
12
6+
**
Alt Alt Alt
OVA OVA OVA OVA
HES
OVA PBS OVA OVA
f
g
0
5
10
15
20
%
 O
f I
CO
S+
lin
ea
ge
-
IL-4 IL-5 IL-13
** **
*****
******
e
0.0
0.2
0.4
0.6
0.8
1.0
Cy
to
kin
e+
IC
O
S+
lin
ea
ge
-
ce
ll 
nu
m
be
rs
 (x
10
5 )
IL-4 IL-5 IL-13
******
** ***
*** ***
0
2
4
6
8
10
Cy
to
kin
e+
CD
4+
Tc
RB
+
ce
ll 
nu
m
be
rs
 (x
10
5 )
IL-4 IL-5 IL-13
*** **
******
******
ih
OVA:OVA
Alt-OVA:PBS
Alt-OVA:OVA
Alt-OVA+HES:OVA
d
Figure 2 Suppression of innate and adaptive type 2 responsiveness by HES. FollowingAlternaria-OVA sensitization and challenge, BAL fluids, lungs,
anddraining lymphnodeswere collected; in someexperiments (g–i), 1 106DO11.10OVA-specific T cellswere transferred tomice before sensitization.
Fluids were assayed for soluble cytokines and markers, and cells stained for cytokines and Foxp3. (a) Cytokines in cell-free BAL supernatant measured
by cytometric beadarray. (b) Type 2myeloid cell responsemarkers inBALmeasured byELISA. (c–f) Intracellular cytokine-positive proportions (c,d) and
absolute numbers (e, f) of lung CD4þTCRbþ T cells (c, e) and ICOSþLineage innate lymphoid cells (d, f). Lung tissue cells were cultured in Phorbol
Myristate Acetate (PMA)/Ionomycin for 4 h in the presence of Brefeldin A, before staining for surfacemarkers and intracellular cytokines. (g) Intracellular
IL-13 expression by ICOSþLineage lung cells. (h) Intracellular IL-4withinDO11.10OVA-specific T cells from the draining lymph nodes co-stainingwith
the clonotypicmarker KJ126. (i) Intracellular Foxp3 expression in the draining lymph nodeCD4þKJ126þ T-cell population. Results are representative or
pooled from at least two repeat experiments with 3–5 mice per group. Unless otherwise indicated differences are not significant. ***Po0.01, **Po0.01,
and *Po0.05. #indicates significance when comparing Alt-OVA:PBS and Alt-OVA:OVA groups, * indicates significance when comparing Alt-OVA:OVA
andAlt-OVA-HES:OVAgroups in panels a–c, or as indicated by bars in panelsd–j. BAL, bronchoalveolar lavage; HES,H. polygyrus excretory-secretory;
OVA, ovalbumin; PBS, phosphate-buffered saline.
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have a disproportionately large role in the production of these
cytokines, and hence the potent suppression of ILC2s by HES
could have a major impact.
HES is more effective at suppressing ILC2 than OVA-
specific T-cell responses
To measure allergen-specific, rather than total, cytokine
responses, we transferred OVA-specific transgenic DO11.10
T cells to mice before sensitization with Alternaria extract,
OVA and HES. As before, we found significant decreases in
lung ILC2 IL-13 production when HES was coadministered
(Figure 2g). In the lung-draining lymph nodes, however, the
marked increase in proportions and numbers of DO11.10
T cells expressing IL-4 in the allergic responders was unaffected
by administration of HES (Figure 2h; Supplementary
Figure 3), with similar results seen in lung DO11.10 cells
(Supplementary Figure 3). We also examined Foxp3 expres-
sion within the transferred DO11.10 population; this was
particularly high in the OVA:OVA control group that did not
receive Alternaria and presumably reflects tolerance induction
by soluble antigen.36 Most notably, following OVA-Alternaria
priming the proportions of DO11.10 cells expressing Foxp3
were unchanged by HES administration (Figure 2i), indicating
that expansion of Foxp3þ regulatory T cells does not readily
account for the suppression of allergy in vivo.
Taken together, these data indicate that in this model HES
suppresses total Th2 responses, but does not appear to suppress
OVA-specific Th2 responses, while suppression of ILC2
responses is very potent. Therefore, we hypothesized that
the suppression of allergic inflammation in this model by HES
is more dependent on suppression of ILC2 than direct
modulation of the OVA-specific T-cell compartment. Thus,
we decided to investigate the role of ILC and the cytokines that
induce them further.
Allergic responses to Alternaria depend on MyD88 and
IL-33, but not on IL-25 or TLR4 stimulation
To ensure thismodel is fully dependent on an adaptive immune
response toOVA, it was repeated in RAG-deficientmice, which
showed no BAL or lung eosinophilic or ILC2 responses at
challenge (Figure 3a,b; Supplementary Figure 4A). As ILC2s
are known to be activated by IL-25 and IL-33,7,20 the course of
allergic inflammation was followed in mice deficient in
IL-17RB (the IL-25-specific subunit of the receptor),
IL17RBxST2 (the IL-25 and IL-33 receptors), and MyD88x-
TRIF, as IL-33 requires MyD88-mediated signal transduction
or TLR4. In IL-17RB-deficient mice, BAL and lung eosinophil
(Figure 3c; Supplementary Figure 4B) and ILC2 (Figure 3d)
responses were similar to those in wild-type BALB/c mice, and
suppression with HES coadministration was equally profound
in the presence or absence of IL-25 signaling. In contrast,
IL17RBxST2-deficientmice had severely reduced BAL and lung
eosinophil and ILC2 responses, and no suppression with HES
administration was evident (Figure 3e,f; Supplementary
Figure 4C). MyD88xTRIF-deficient mice had no detectable
BAL or lung eosinophilic or ILC2 response with any treat-
ment (Figure 3g,h; Supplementary Figure 4D). Finally,
TLR4-deficient mice showed similar levels of BAL and
lung eosinophilia, and ILC2 IL-13 production (Figure 3i,j;
Supplementary Figure 4E). As MyD88, but not TLR4
signaling, was found to be required for the type 2 response
to Alternaria,37 and Alternaria has been reported to stimulate
high levels of IL-337,17 it is likely that the inability of
MyD88xTRIF-deficient mice to respond in our model is
due to the lack of IL-33 signaling. Taken together, these results
indicate an important role for IL-33 (but not IL-25 or TLR4)
signaling in this model.
HES suppresses early innate responses to Alternaria
Alternaria administration is known to induce ILC2 responses
and eosinophil accumulation in the first days after adminis-
tration, in a mechanism dependent on IL-33 signaling, before
and independent of involvement of the adaptive immune
system.7,17We therefore tracked the immune response over the
first 48 h following the in vivo exposure to Alternaria and HES.
In this setting, HES coadministration completely ablated the
BAL and lung eosinophil response to Alternaria (Figure 4a,b).
To accurately assay ILC2 activation (in the absence of Phorbol
Myristate Acetate/Ionomycin stimulation), we administered
Alternaria/HES to IL-13-GFP reporter mice, and found sub-
stantial suppression by HES of the expansion of IL-13-GFPþ
ILC2s at 48 h post administration which were lineage negative
but ICOSþ , CD44þ , and CD25þ (Figure 4c; Supplementary
Figure 5).We also assessed ILC2 intracellular cytokine produc-
tion over the first 48 h afterAlternaria/HES administration and
found decreased ILC2 production of IL-4, IL-5, and IL-13
(Figure 4d–f). As in theAlternaria-OVAmodel, whenHESwas
heat treated, it lost its ability to suppress early eosinophilia and
ILC2 IL-13 production (Figure 4g,h). To address the role of the
TGF-b mimic in HES, we again administered recombinant
TGF-b, and were not able to replicate the suppressive effect of
HES (Figure 4i). To discount any T-cell contribution to this
effect, we repeated the exposure in RAG-deficient mice; despite
the absence of adaptive lymphocytes, marked eosinophilia
(Figure 4j) and ILC2 expression of IL-13 were observed at 48 h
followingAlternaria administration (Figure 4k), both of which
were suppressed by HES. In addition, we were able to exclude a
physical effect, such as digestion, of HES upon Alternaria
extract by replicating suppression in mice given HES 6 h before
the separate administration of Alternaria (Figure 4l).
HES suppresses Alternaria-induced IL-33 release
To capture the early events followingAlternaria exposure, BAL
and lung tissue samples were analyzed for cytokines and type 2
markers at 1, 24, and 48 h post administration with andwithout
HES (Figure 5a–d). BAL IL-5, RELM-a, and Ym1 were all
induced by 24 h after Alternaria administration, and these
responses were all suppressed by HES coadministration
(Figure 5a–c). These responses are all independent of the
adaptive immune system, as they are unchanged in RAG-
deficient mice (Supplementary Figure 6). IL-33 was only
detectable in the BAL 1 h after Alternaria administration
(Figure 5d) as reported previously,7,17 and was also potently
suppressed by HES at this time point. Similarly to the effects
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Figure 3 Alternaria-induced allergic reactivity is dependent on both innate and adaptive immune compartments in an IL-25-independent manner. The
response to Alternaria-OVA administration was tested in mice deficient in recombinase-activating gene (RAG)-2 (a, b), IL-17RB (c, d), IL-17RBxST2
(e, f), MyD88xTRIF (g, h), or TLR4 (i, j) and their congenic wild-type strains; bronchoalveolar lavage (BAL) fluids were assayed for SiglecFþCD11c–
eosinophils (a,c,e,g, and i) and lung cell populations for intracellular IL-13 stainingwithin the ICOSþLineage subset (b,d, f,h, and j). Unless otherwise
indicated differences are not significant. ***Po0.01, **Po0.01, and *Po0.05. OVA, ovalbumin.
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seen at later time points, the suppression of IL-33 at 1 h by HES
was again shown to be heat labile (Figure 5e). Finally, to
confirm the active production of IL-33 by live cells, we utilized
IL-33-Citrine reporter mice,21 which showed upregulation of
IL-33 expression in epithelial cells after Alternaria adminis-
tration, and a suppression of this response with HES
(Figure 5f). Suppression of IL-33 reporter expression was
also evident in the Alternaria/OVA model, with a significant
upregulation of IL-33-Citrine in allergic mice, and suppression
when HES was coadministered with the sensitizing dose
(Figure 5g; Supplementary Figure 7).
Recombinant IL-33 administration abrogates HES
suppression
As the proximal event in the Alternaria-induced response
appears to be IL-33 production, and that response is suppressed
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by HES, we evaluated whether provision of exogenous IL-33
would circumvent HES suppression of downstream eosino-
philia and ILCs activation. First, the short-term in vivo response
to IL-33 itself in RAG-deficient mice, given in the absence of
Alternaria, was tested. As shown in Figure 6a–c, although HES
could slightly decrease the BAL eosinophilic response to IL-33,
both lung eosinophilia and ILC2 IL-13 production were
unchanged.
Finally, we investigated whether the ability of exogenous
IL-33 to short-cut HES suppression also pertained to the
development of the adaptive allergic response to OVA
challenge in the airways. Mice were sensitized with Alter-
naria-OVA, with or without HES and recombinant IL-33, as
shown in Figure 6d. The reduction in BAL eosinophilia with
HES (Figure 6e), the Th2 response in the lung (Figure 6f), and
the ILC2 IL-13þ response (Figure 6g) were all negated by a
single administration of IL-33 at sensitization only.
DISCUSSION
The ability of helminth infections to downmodulate allergic
reactivity in vivo31,33,38 has stimulated the search for molecular
mechanisms of suppression that may offer new routes to
prevention and treatment of allergic disease in humans. An
important step toward this goal is that non-living secreted
products of these parasites can recapitulate protection against
allergy in vivo.4 We now show that HES, secreted by
H. polygyrus, suppresses the early IL-33 to Alternaria and
suppresses the later type 2 (especially ILC2) allergic response.
This is the first example to our knowledge of a soluble parasite
product suppressing early alarmin and ILC pathways.
Our results do not exclude pathways of suppression other
than reduced IL-33 release by HES in allergic responses, in fact
it seems likely that H. polygyrus has developed a plethora of
suppressive molecules to act against type 2 immune responses
at multiple levels. However, we believe the most likely
mechanism of HES suppression in this model is blockade
of early IL-33 release upon allergen administration, leading to a
smaller early ILC2 response, and smaller allergic recall
responses at later time points.
IL-33 is a pivotal alarm cytokine in infection and allergy,
directly stimulating not only ILCs,7 but also macrophages,
osteoclasts, Th2 cells, mast cells, DCs, and other subsets
expressing T1/ST2, the IL-33 receptor.39 Downstream IL-33
elicits high levels of IL-5 and IL-13 production by IL-33-
stimulated ILC2s, culminating in a potent pro-allergic response
that can be protective against helminth infection. Hence, the
ability of helminth products to inhibit IL-33 release may have
evolved to promote parasite survival, and can account for some
of the anti-allergic effects of parasite infection in vivo. Indeed,
IL-33 itself can promote immunity to nematodes,40,41 and
IL-33-deficient mice are impaired in their expulsion of parasite
species such as Nippostrongylus brasiliensis.20
HES suppressed IL-33 responses to Alternaria administra-
tion; however, the upstream mechanisms involved in IL-33
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release are still somewhat controversial. It is established that
IL-33 does not require caspase-mediated cleavage to activate its
receptor, unlike the related IL-1-family members IL-1b and
IL-18, suggesting that it acts as an alarmin molecule, released
when cells undergo necrosis.42 Indeed, rather than being
converted into an active form during apoptosis, IL-33 is
inactivated by caspases,43 inferring that it serves as a danger
signal released under damage-induced, but not programmed,
cell death. However, living cells can also release IL-33 in
response to mechanical stress,44 danger signals such as ATP,17
the epithelial-derived factor Trefoil Factor 2,45 and indeed
IL-33 itself induces IL-33 transcription in live cells.21 Therefore,
IL-33 released by dying cells may induce further IL-33 pro-
duction by healthy cells.
It is possible thatHES acts solely in the extracellularmilieu to
suppress IL-33 release, for example, by reducing levels of
extracellular ATP. Several active apyrases have been identified
in HES,46 which degrade ATP and ablate its ability to bind to
inflammatory purinergic signaling receptors. Alternatively, as
macrophage IL-33 production is suppressed by endogenous
TGF-b,47 the TGF-b activity of HES29 could have a similar role
in this model. When we attempted to replicate the effects of
HES by using recombinant mammalian TGF-b, however, we
saw no effect. The possibilities remain, however, that the HES
TGF-bmimic is more efficacious in vivo and/or acts in synergy
with other HES components.
An intriguing finding in the recall setting, in which
AlternariaþOVA-primed mice were challenged in airways
with OVA, is that ILC2 responses were found to be T cell
dependent, as they were absent from RAG-deficient mice or
from intact mice sham challenged with PBS after Alternaria/
OVA sensitization. The T-cell factor responsible for ILC2
induction is unknown, but it is tempting to speculate that T-cell
IL-2 is responsible asAlternaria-responsive lung ILC2s express
the IL-2 receptor CD257 and IL-2 can activate ILC2s.48
The suppression of allergic responses by soluble parasite
mediators has major implications for the Hygiene Hypothesis
and the search for novel therapeutic agents against allergic
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disease. The suppression of initial IL-33 production has a clear
effect upon ILC2 generation, and most likely impacts on
activation of other innate cell types, which together enables the
parasite to survive in the host. Further, these changes can help
explain the observation that parasite-infected individuals have
a lower probability of developing allergy and asthma.
Identification of the parasite immunomodulators involved
in this suppression could result in the development of novel
therapeutic agents that may be used to replicate the protective
effects of parasitic infection at the molecular level, resulting in
new strategies for protection against allergic disease.
METHODS
Parasites and reagents. The life cycle of H. polygyrus bakeri was
maintained, and HES products prepared, as described elsewhere.49
Class IV Ovalbumin (Sigma, Gillingham, Dorset, UK) was lipopo-
lysaccharide (LPS) depleted by Triton X-114 phase separation,50 and
the levels of LPS present in HES and depleted OVAwere below 0.1 and
0.01 IU LPS per mg protein respectively by the Limulus Amoebocyte
Lysate assay (Lonza, Slough, UK). HES was heat inactivated at 95 1C
for 20min. A. alternata extract (Greer) was dissolved in PBS and filter
sterilized. Bovine Serum Albumin (BSA) was purchased from Sigma.
The carrier-free recombinant TGF-b and IL-33 (R&D Systems,
Abingdon, UK) was dissolved in sterile PBS.
Mice. BALB/c, C57BL/6, IL-17BR-deficient, IL-17BRxST2-double
deficient, MyD88xTRIF-double deficient, TLR4-deficient, RAG-2-
deficient, DO11.10, IL-33-Citrine,21 and IL-13-GFP20 mice were bred
in-house at theUniversity of Edinburgh and accommodated according
to Home Office regulations.
Airway allergy models. In early time-point experiments, 5 mg HES
was administered with 50 mg Alternaria extract in 50ml PBS. Mice
were killed 1, 24, or 48 h later as indicated. In the AlternariaþOVA
model (see Figure 1a), 20 mg LPS-depleted OVA protein, 50 mg
Alternaria extract, and/or 10mg HES were administered intranasally
in 50ml PBS. Challenges of 20 mg OVA protein in 50 ml PBS were
administered intranasally on days 14, 15, and 16 after sensitization,
and mice killed on day 17. In some experiments, 20 mg BSA, 200 ng
rIL-33, or 4 ng rTGF-b was coadministered with Alternaria extract.
For DO11.10 cell transfer, single-cell suspensions of spleen and
lymph-node cells were CD4þ purified by MACS separation
(Miltenyi Biotec, Bisley, UK) according to the manufacturer’s instruc-
tions. In all, 1 106 CD4þ cells were transferred by intravenous
injection.
Tissue preparation. At kill, bronchoalveolar cells were prepared by
lavaging lungs with 500ml PBS containing 0.5% BSA (for cytokine
measurement in cell-free supernatant), followed by another three
lavages to collect remaining cells. Single-cell suspensions of lung tissue
were prepared by digesting the right lobes of the lung in 2Uml 1
liberase TL (Roche, Burgess Hill, UK) and 80Uml 1 DNase (Life
Technologies, Paisley, UK) at 37 1Cwith agitation for 35min.Draining
mediastinal lymph nodes and digested lung tissue were macerated
through 70mm cell strainers. For histology, lungs were inflated with,
and collected into, 10% buffered formalin, incubated overnight at 4 1C,
then transferred to 70% ethanol, paraffin embedded and sectioned, and
stained following standard protocols for Hemotoxylin and Eosin and
Periodic Acid Schiff.
Flow cytometry. Cells were surface stained with fluorescently labeled
antibodies to CD11c, SiglecF, Gr1, CD11b, CD4, TcRb, CD3, CD19,
CD8a, CD49b, KJ1–26, ICOS, CD25, CD44, and ST2 or the relevant
isotype controls. For intracellular Foxp3 staining, the eBioscience
Foxp3 Fix/Perm kit (eBioscience, Hatfield, UK) was used. For
intracellular cytokine staining, cells were stimulated for 4 h at 37 1C
with 500 ngml 1 Phorbol Myristate Acetate, 1 mgml 1 Ionomycin,
and 10 mgml 1 Brefeldin A (Sigma). Cells were surface stained, then
permeabilized with the BD Biosciences Fixation/Permeabilisation kit
(BD Biosciences, Oxford, UK) before staining for IFN-g, IL-4, IL-5,
IL-10, IL-13, and IL-17A. Live/dead Fixable Yellow or Aqua dyes
(Invitrogen) were used to exclude dead cells. Samples were analyzed by
flow cytometry using Becton-Dickinson FACSCanto or LSR-II flow
cytometers (BD Biosciences). Cell types were characterized as:
CD11cþSiglecFþ (alveolar macrophages), SiglecFþCD11c–CD11bþ
GR1lo (eosinophils), Gr1hiCD11bhiCD11c–SiglecF– (neutrophils)
and CD4þCD11b (T helper cells). ILC2s were characterized as
lineage– (CD3/CD19/CD4/CD5/CD8a/TcRb/CD49b/CD11b/CD11c)
and ICOSþ.
ELISA. RELM-a and Ym-1 were measured by ELISA, using rabbit
anti-mouse RELM-a, and biotinylated rabbit anti-mouse RELM-a,
compared with a recombinant RELM-a standard (Peprotech, London,
UK), or the Chitinase 3-like/ECF-L (Ym1) DuoSet kit (R&D Systems)
according to the manufacturer’s instructions. IL-33 was measured
using the R&D Systems ELISA kit according to the manufacturer’s
instructions.
Cytokine Bead Array. Cytokine levels were detected in cell-free BAL
supernatant. IL-4, IL-5, IL-10, IL-13, IFN-g, and IL-17A levels were
detected using BD cytometric bead array Flex-set kits (BD Bios-
ciences), and were acquired on a BD FACSArray.
Statistics. All data were analyzed using Prism 6 (Graphpad Prism, La
Jolla, CA). Groups were analyzed by one-way ANOVA, with a Sˇı´da´k’s
multiple comparisons post test comparing all groups with the OVA
only positive control. Unless otherwise indicated differences are not
significant. ***Po0.001, **Po0.01, *Po0.05.
SUPPLEMENTARYMATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
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